GLP-1 RAs are recommended as initial injectable therapy for T2DM due to their efficacy in glucose control, weight reduction, and cardiovascular benefits, particularly in high-risk patients with cardiovascular disease. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.